Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Abstract Effective public-health measures and vaccination campaigns against SARS-CoV-2 require granular knowledge of population-level immune responses. We developed a Tripartite Automated Blood Immunoassay (TRABI) to assess the IgG response against the ectodomain and the receptor-binding domain of the spike protein as well as the nucleocapsid protein of SARS-CoV-2. We used TRABI for continuous seromonitoring of hospital patients and healthy blood donors (n=72’222) in the canton of Zurich from December 2019 to December 2020 (pre-vaccine period). Seroprevalence peaked in May 2020 and rose again in November 2020 in both cohorts. Validations of results included antibody diffusional sizing and Western Blotting. Using an extended Susceptible-Exposed-Infectious-Removed model, we found that antibodies waned with a half-life of 75 days, whereas the cumulative incidence rose from 2.3% in June 2020 to 12.2% in mid-December 2020 in the population of the canton of Zurich. A follow-up health survey indicated that about 10% of patients infected with wildtype SARS-CoV-2 sustained some symptoms at least twelve months post COVID-19 and up to the timepoint of survey participation. Crucially, we found no evidence for a difference in long-term complications between those whose infection was symptomatic and those with asymptomatic acute infection. The cohort of asymptomatic SARS-CoV-2- infected subjects represents a resource for the study of chronic and possibly unexpected sequelae.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stan : A Probabilistic Programming Language
Carpenter, B., Gelman, A., Hoffman, M. D., Lee, D., Goodrich, B., Betancourt, M., Brubaker, M., Guo, J., Li, P., & Riddell, A. (2017) · Journal of Statistical Software · doi:10.18637/jss.v076.i01 · Cited by 7,754 · cited 1×
“56 The model was fitted in a Bayesian framework using Stan, 82 by which the 95% credible intervals were computed through MCMC sampling.”
Self-citationAntibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2550-z · Cited by 1,887
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769 · cited 1×
“We have screened 17,901 samples for antibodies against three SARS2related antigens: the ectodomain of the spike protein (S), its receptor-binding domain (RBD) and the nucleocapsid protein (NC), using SARS2 enzyme-linked immunoassays (ELISA) [4-6].”
Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M., Sanmartín, J. L., Fernández-García, A., Cruz, I., Fernández de Larrea, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31483-5 · Cited by 1,639
Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614
Bias and causal associations in observational research
Grimes, D. A., & Schulz, K. F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07451-2 · Cited by 1,553
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Cited by
Levin, A. T., Hanage, W. P., Owusu-Boaitey, N., Cochran, K. B., Walsh, S. P., & Meyerowitz-Katz, G. (2020) · European Journal of Epidemiology · doi:10.1007/s10654-020-00698-1 · Cited by 844
Infection fatality rate of COVID-19 inferred from seroprevalence data
Ioannidis, J. P. A. (2021) · Bulletin of the World Health Organization · doi:10.2471/blt.20.265892 · Cited by 684
Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19
Cervia, C., Nilsson, J., Zurbuchen, Y., Valaperti, A., Schreiner, J., Wolfensberger, A., Raeber, M. E., Adamo, S., Weigang, S., Emmenegger, M., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.10.040 · Cited by 408
Self-citationPersistent complement dysregulation with signs of thromboinflammation in active Long Covid
Cervia-Hasler, C., Brüningk, S. C., Hoch, T., Fan, B., Muzio, G., Thompson, R. C., Ceglarek, L., Meledin, R., Westermann, P., Emmenegger, M., et al. (2024) · Science · doi:10.1126/science.adg7942 · Cited by 408
Self-citationPerformance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison
Ainsworth, M., Andersson, M., Auckland, K., Baillie, J. K., Barnes, E., Beer, S., Beveridge, A., Bibi, S., Blackwell, L., Borak, M., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30634-4 · Cited by 351
Self-citation
Metadata
- Authors
- Emmenegger, M., De Cecco, E., Lamparter, D., Jacquat, R. P. B., Riou, J., Menges, D., Ballouz, T., Ebner, D., Schneider, M. M., Morales, I. C., Doğançay, B., Guo, J., Wiedmer, A., Domange, J., Imeri, M., Moos, R., Zografou, C., Batkitar, L., Madrigal, L., Schneider, D., Trevisan, C., Gonzalez-Guerra, A., Carrella, A., Dubach, I. L., Xu, C. K., Meisl, G., Kosmoliaptsis, V., Malinauskas, T., Burgess-Brown, N., Owens, R., Hatch, S., Mongkolsapaya, J., Screaton, G. R., Schubert, K., Huck, J. D., Liu, F., Pojer, F., Lau, K., Hacker, D., Probst-Müller, E., Cervia, C., Nilsson, J., Boyman, O., Saleh, L., Spanaus, K., von Eckardstein, A., Schaer, D. J., Ban, N., Tsai, C.-J., Marino, J., Schertler, G. F. X., Ebert, N., Thiel, V., Gottschalk, J., Frey, B. M., Reimann, R. R., Hornemann, S., Ring, A. M., Knowles, T. P. J., Puhan, M. A., Althaus, C. L., Xenarios, I., Stuart, D. I., & Aguzzi, A.
- Venue
- iScience
- Publisher
- Elsevier BV
- Published
- 2023-02
- Volume
- 26
- Issue
- 2
- Pages
- 105928
- ISSN
- 2589-0042 (ISSN-L)
- OpenAlex
- W3033104764
- Cited by
- 39
- References
- 25
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region. https://app.cochat.ai/papers/10.1016/j.isci.2023.105928
- The paper
- Emmenegger, M., De Cecco, E., Lamparter, D., Jacquat, R. P. B., Riou, J., Menges, D., Ballouz, T., Ebner, D., Schneider, M. M., Morales, I. C., Doğançay, B., Guo, J., Wiedmer, A., Domange, J., Imeri, M., Moos, R., Zografou, C., Batkitar, L., Madrigal, L., . . . Aguzzi, A. (2023). Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region. iScience. https://doi.org/10.1016/j.isci.2023.105928
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.